Prevalence, Clinical Features, and Prognosis of Coronary Artery Embolism With Concomitant Atrial … (NCT06845956) | Clinical Trial Compass
CompletedNot Applicable
Prevalence, Clinical Features, and Prognosis of Coronary Artery Embolism With Concomitant Atrial Fibrillation
China5,163 participantsStarted 2024-05-01
Plain-language summary
The goal of this observational study is to learn about the Prevalence, Clinical Features, and Prognosis of Coronary Artery Embolism With Concomitant Atrial Fibrillation. The main question it aims to answer is:
What is the proportion of coronary artery embolism with concomitant atrial fibrillation among all myocardial infarctions and myocardial infarctions with concomitant atrial fibrillation? What are the clinical characteristics of coronary artery embolism with concomitant atrial fibrillation? What is the prognosis of coronary artery embolism with concomitant atrial fibrillation? All participants will receive routine diagnosis and treatment, and baseline demographic data, clinical examination laboratory results, and follow-up data will be collected for analysis.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinical diagnosis of Acute myocardial infarction
* Selective coronary angiography has been performed.
Exclusion Criteria:
* Clinical diagnosis of Iatrogenic coronary artery embolism
* Clinical diagnosis of Coronary artery dilation
* Clinical diagnosis of Coronary in-stent thrombosis and embolism
* Clinical diagnosis of Coronary slow flow syndrome
* Clinical diagnosis of Coronary artery dissection
* Clinical diagnosis of Coronary artery spasm
* Pathological examination showed that the embolus contained atherosclerotic plaque
* Endovascular imaging examinations, including intravascular ultrasound (IVUS) and optical coherence tomography (OCT), indicate the presence of plaque rupture, erosion, or ulceration in the culprit vessel.
* Clinical diagnosis of Previous myocardial infarction
* Previous coronary stent implantation or coronary artery bypass surgery.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
All-cause death, cardiogenic death
Timeframe: Up to 10 years
2
Major Adverse Cardiovascular and Cerebrovascular Events
Timeframe: Up to 10 years
3
Systemic thrombo-embolism
Timeframe: Up to 10 years
4
Major hemorrhage
Timeframe: Up to 10 years
Trial details
NCT IDNCT06845956
SponsorFirst Affiliated Hospital of Ningbo University